Comparative evaluation of efficacy and safety of primaquine sustained-release tablets v/s primaquine conventional tablets in Treatment and prevention of relapse of plasmodium vivax malaria

Vishnu Kumar Gupta, Gopal Jhalani, Harsh Yadav, Arvind Verma, Shivankan Kakkar


Background: Malaria is one of the most important parasitic disease of human. In India 60-65% of infections are due to P.vivax and 35-40% are due to P.falciparum Malaria is an acute, recurrent and sometimes chronic vector borne protozoan disease which has worldwide distribution in tropical and subtropical regions The role of Primaquine is well established in the prevention of relapse of P.vivax malaria. Primaquine has a narrow therapeutic range and short half-life that requires daily administration upto 2 weeks, resulting in poor compliance

Methods: Randomized control trial, which involved 100 patients of P.vivax Malaria Patient in medical ward of mahatma Gandhi hospital attached to S N medical college ’Jodhpur. All patient in this study received chloroquine for 3 days (10mg of base per kg followed by 5mg /kg 6-8 hours later and 5 mg/kg on each of the two days, total 25mg/kg over 3days and divided in three groups viz.Group 1 taken Primaquine 15 mg tab for 14 days (n=34), Group 2 taken Primaquine 15 mg SR tab for 14 days (n=33),Group 3 taken Primaquine 30 mg SR tab for 7 days and placebo for next 7 days.

Results: In this study, Efficacy and compliance of Primaquine 30 mg SR for 7 days was found greater than the conventional Primaquine tab. and Primaquine 15 mg SR tab for 14 day. Adverse effect of primaquine 30 mg SR tab for 7 days was found lesser than conventional Primaquine tab 15 mg as well as Primaquine 15 mg SR tab.

Conclusions: As Malaria is very prevalent in India which causes significant mortality and morbidity in Indian population. Use of Primaquine 30 mg SR tab has good compliance, efficacy as well as lesser adverse effect.


Malaria, P. Vivax, Primaquine SR, Randomized control trial

Full Text:



Lee GR, Bithel TC, Foerster JA, Athens JW, Leukens JN. Wintrobe’s Clinical hematology. 9th ed. London, Lea and Febiges; 1993:198-1201.

Mepherson RA, Pincus MR. Blood and Tissue Protozoa, Henry’s Clinical Diagnosis and Management by Laboratory Methods, 22nd ed. Elsevier; 2007:1127-34.

Park KS. Arthropod born infection, Park’s textbook of Preventive and Social Medicine. 15th ed. Jabalpur; 1997:188-202.

Kumar AK, Shashirekha PB. Thrombocytopenia- an indication of acute vivax malaria. Indian J Pathol Microbiol. 2006;49:505-8.

Park KS. Arthropod born infection, Park’s textbook of Preventive and Social Medicine. 15th ed. Jabalpur; 1997:209-220.

Nank NA, Aggraval HM, Sharma MD, Singh MK. Systemic Manifestation of Malaria. J Ind Acad of ClinMed 2007;2(3):189-204.

Rodriguez AJ, Morales E, Sanchez M, Vargas C, Piccolo R, Colina M. Clinical infectious disease, 2005:130-131.

Sharma SK, Das RK, Das BK, Das P.K. Hematological profile in acute falciparum malaria. J. Assoc. Physicians India. 1992;40:581-3.

Kakar A, Bhoi S. Profound thrombocytopenia in plasmodium malaria. Diagn Microbiol Infect Dis. 1999;35:243-.4

Gogtay NJ, Desai S, Kamtekar KD, Kadam KD, Dalvy SS, Kshirsagar NA. Efficacy of 5 and 14 day primaquine therepy in prevention of relapse in p.vivax infection. Ann trop med parasitol. 1999;93(8):809-12.

Collins WE, Jeffery GN. Primaquine in P.vivax, am J Trop Med Hyg. 1996;55:243-9.

Clyde DF. Clinical problems associated with the use of primaquine as a schizonticidal and gamitocidal drug. bull WHO. 1981;59:391-5.